AVIR logo

AVIRAtea Pharmaceuticals Inc

$4.25
$0.17
(3.85%)
Today
Closed $4.25
$0.00
(0.00%)
After Hours
Updated: 04:30 PM EDT
Reported EarningsMay 12
Mkt Cap$340.12M
Vol217,602.00
41

Bearish Sentiment

How do you feel about AVIR?

News
all
press releases
Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround
Atea Pharmaceuticals (AVIR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks
News Placeholder
More News
News Placeholder
Atea Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript
read more...
Benzinga
News Placeholder
Atea Pharmaceuticals (AVIR) Expected to Announce Quarterly Earnings on Tuesday
Atea Pharmaceuticals (NASDAQ:AVIR) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-atea-pharmaceuticals-inc-stock...
MarketBeat
News Placeholder
Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Up 1.6% - Still a Buy?
Atea Pharmaceuticals (NASDAQ:AVIR) Shares Up 1.6% - Time to Buy...
MarketBeat
News Placeholder
Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Up 5.9% - Here's Why
Atea Pharmaceuticals (NASDAQ:AVIR) Shares Up 5.9% - Time to Buy...
MarketBeat
News Placeholder
Atea Pharmaceuticals (NASDAQ:AVIR) Hits New 12-Month High - Here's Why
Atea Pharmaceuticals (NASDAQ:AVIR) Hits New 1-Year High - What's Next...
MarketBeat
News Placeholder
Atea Pharmaceuticals Q4 Earnings Call Highlights
Atea Pharmaceuticals (NASDAQ:AVIR) outlined progress in its hepatitis C (HCV) late-stage development program and provided an update on its newly expanded hepatitis E virus (HEV) pipeline during its...
MarketBeat
News Placeholder
Atea Pharmaceuticals (NASDAQ:AVIR) Posts Earnings Results, Misses Expectations By $0.08 EPS
Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus...
MarketBeat
News Placeholder
Insights Ahead: Atea Pharmaceuticals's Quarterly Earnings
read more...
Benzinga
News Placeholder
Atea Pharmaceuticals (AVIR) to Release Quarterly Earnings on Thursday
Atea Pharmaceuticals (NASDAQ:AVIR) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 5. (View Earnings Report at...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.